Javier Pascual

Malaga, AN 29010, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 33 publications

SERENA-6 visual patient-reported outcomes & safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy.

SERENA-6 visual patient-reported outcomes & safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy.

Journal: The oncologist

Published: May 22, 2026

SERENA-6 visual patient-reported outcomes and safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy.

SERENA-6 visual patient-reported outcomes and safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy.

Journal: The oncologist

Published: May 22, 2026

Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial.

Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial.

Journal: The Lancet. Oncology

Published: April 24, 2026

SERENA-6 interpretation and clinical implications: intercepting endocrine resistance in metastatic breast cancer.

SERENA-6 interpretation and clinical implications: intercepting endocrine resistance in metastatic breast cancer.

Journal: NPJ breast cancer

Published: March 09, 2026

Dual ctDNA and CTCs analysis for minimal residual disease detection and relapse monitoring in early-stage breast cancer.

Dual ctDNA and CTCs analysis for minimal residual disease detection and relapse monitoring in early-stage breast cancer.

Journal: NPJ breast cancer

Published: February 25, 2026

Association between antibiotic use and pathologic response to neoadjuvant chemotherapy in breast cancer: a multicentre retrospective cohort study.

Association between antibiotic use and pathologic response to neoadjuvant chemotherapy in breast cancer: a multicentre retrospective cohort study.

Journal: Breast (Edinburgh, Scotland)

Published: February 13, 2026

The landscape of clonal hematopoiesis of indeterminate potential in long-term breast cancer survivors.

The landscape of clonal hematopoiesis of indeterminate potential in long-term breast cancer survivors.

Journal: Breast (Edinburgh, Scotland)

Published: January 07, 2026

UGT2B17 as a predictive biomarker of complete pathological response in HER2 + breast cancer.

UGT2B17 as a predictive biomarker of complete pathological response in HER2 + breast cancer.

Journal: Breast cancer (Tokyo, Japan)

Published: November 24, 2025

Real-world effectiveness and safety of Sacituzumab Govitecan in metastatic triple-negative breast cancer: results from the multicenter retrospective observational SACISUR cohort in Southern Spain.

Real-world effectiveness and safety of Sacituzumab Govitecan in metastatic triple-negative breast cancer: results from the multicenter retrospective observational SACISUR cohort in Southern Spain.

Journal: Frontiers in oncology

Published: October 01, 2025

Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy.

Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: September 05, 2025

Real-world data analysis of adjuvant capecitabine for triple-negative breast cancer after neoadjuvant chemotherapy.

Real-world data analysis of adjuvant capecitabine for triple-negative breast cancer after neoadjuvant chemotherapy.

Journal: Frontiers in oncology

Published: June 16, 2025

First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer.

First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer.

Journal: The New England journal of medicine

Published: June 02, 2025

Showing 1-12 of 33

Last Updated: 09/26/2026